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Volume 49, Number 2 Abstracts 535have changed. However, many requirements must be in place for EVAR to
be a viable alternative to open repair for patients with rAAAs. Such factors
include available surgical expertise, available nursing expertise, and of
course, available devices at all times in the operating room. It seems unlikely,
unless an institution has large exposure to patients with rAAAs, that all of
these things would come together with sufficient frequency that EVAR
repair of rAAAs will exceed open repair of rAAAs in the near future.
Effects of Extended-Release Metoprolol Succinate in Patients Under-
going Non-Cardiac Surgery (POISE Trial): A Randomized Controlled
Trial
POISE Study Group. Lancet 2008;371:1839-47.
Conclusion: The use of perioperative -blockade in patients undergo-
ing noncardiac surgery results in a decrease in the composite end point of
cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac
arrest, but results in an increased risk of death from all causes and stroke.
Summary: Trials of routine use of -blockers in patients undergoing
noncardiac surgery have reported conflicting results. The authors performed
a randomized controlled trial in 190 hospitals in 23 countries to investigate
the effects of perioperative -blockers. Initially, 9280 patients with, or at risk
of, atherosclerotic disease and undergoing noncardiac surgery were random-
ized to receive extended-release metoprolol succinate or placebo. Unfortu-
nately, it was determined that there were fraudulent data from six hospitals
in Iran (752 participants) and three hospitals in Columbia (195 partici-
pants). These patients were excluded from the data, leaving 8351 patients
from 190 hospitals in 23 countries for analysis.
There were 4174 persons randomized to receive metoprolol and 4177
to receive placebo. Medication was administered 2 to 4 hours before surgery
and continued for 30 days. Outcome adjudicators, data collectors, and
health care providers for the individual patients were masked to treatment
allocation. The primary end point was a composite end point of nonfatal
myocardial infarction, nonfatal cardiac arrest, and cardiovascular death.
Analysis was by intention to treat. The analysis included 8351 patients, and
8331 (99.8%) completed the 30-day follow-up.
In the metoprolol group, 244 (5.8%) reached the primary end point vs
290 (6.9%) in the placebo group (hazard ratio [HR], 0.84; 95% confidence
interval [CI], 0.70-0.99; P  .0399). Fewer patients in the metoprolol
group sustained myocardial infarction vs the placebo group (176 [4.2%] vs
239 [5.7%]; HR, 0.73; 95% CI, 0.60-0.89; P .0017). More overall deaths
occurred in the metoprolol group than in the placebo group (129 [3.1%] vs
97 [2.3%]; HR, 1.33; 95% CI, 1.03-1.74; P  .0317). More strokes
occurred in the metoprolol group than the placebo group (41 [1.0%] vs 19
[0.5%]; HR, 2.17; 95% CI, 1.26-3.74; P  .0053). Predetermined sub-
group analyses for region, whether on-site monitoring occurred, and based
on the presence of known atherosclerotic cardiovascular disease did not
show subgroup effects. Post hoc multivariable analysis indicated clinically
significant hypotension contributed to the risk for death and stroke.
Comment:The study has potentially huge implications but needs to be
interpreted with caution. Although it is routine to treat patients with
atherosclerotic risk factors undergoing high-risk surgery with perioperative
-blockers, -blockade was begun only 2 to 4 hours before surgery in this
study. The results may not apply to patients with more extended periods of
treatment with preoperative -blockers. The data indicate that under the
conditions of the trial, extended-release metoprolol can reduce the risk of
myocardial infarction. This, however, is at a cost of an increased risk of death,
stroke, and clinically significant hypotension. The authors also performed a
number of meta-analyses of trials of -blockers. Analysis of nine trials,
including Perioperative Ischemic Evaluation Study (POISE), in which at
least one patient had a fatal myocardial infarction, also indicated -blockers
reduced the risk of myocardial infarction and increased the risk of nonfatal
stroke (HR, 2.19; 95% CI, 1.26-3.78; P .005). The authors point out that
for every 1000 patients undergoing noncardiac surgery, and with similar risk
profiles to those in POISE, extended-release metoprolol can be expected to
prevent 15 myocardial infarctions and prevent seven patients from undergo-
ing new clinically significant atrial fibrillation. However, extended-release
metoprolol will also result in an excess of eight deaths and five additional
patients having a stroke, with 53 experiencing clinically significant hypoten-
sion and 42 experiencing clinically significant bradycardia.
Once again an accepted axiom of perioperative care appears to have
been refuted by a large randomized trial. Vascular surgeons may need to
reconsider the use of routine perioperative -blockade in their patients.
Major Lower Extremity Amputation after Multiple Revascularizations:
Was It Worth It?
Reed AB, Delvecchio C, Giglia JS. Ann Vasc Surg 2008;22:335-40.
Conclusions: The large majority of patients who undergo amputation
after multiple attempts at revascularization would still opt to do everything
possible to save the leg.Summary: Both lesion-specific and patient-specific outcomes are im-
portant in the assessment of treatments for lower extremity arterial occlusive
disease. In particular, lower extremity revascularization is often described as
lesion-centric, with excessive focus on treatment of the lesion and inade-
quate assessment of patient quality of life. The authors sought to investigate
patients’ perspectives of multiple procedures for limb salvage that eventually
cumulated in amajor lower extremity amputation. Patients who had undergone
below knee or above knee amputation after failed lower extremity revascular-
ization were surveyed by telephone by a vascular nurse. Patients were asked
about undergoingmultiple procedures for limb salvage, involvement in decision
making, functional status, use of a prosthesis, and independence. Patientswhose
amputations were performed for infection were excluded.
There were 78 patients who underwent an above or below knee
amputation after failed revascularization; of these, 46 (59%) were alive at 5
years, and 13 were lost to follow-up, leaving 33 available for inclusion in the
survey. These patients had a total of 142 lower extremity revascularizations
(median, 4 per patient), including 94 surgical bypasses and 48 percutaneous
interventions. According to the survey results, 85% of the amputees (28 of
33) would do everything to save the leg if faced with a similar scenario,
regardless of the number of procedures required. Thirty of 33 patients (91%)
resided at home, and 18 of 33 (54%) used a prosthesis.
Comment: The authors conclude patients are willing to undergo
multiple revascularizations in an attempt to salvage a limb even if the
eventual result is amputation. However, only survivors who appeared to be
doing reasonably well were available for participation in this survey, and
only 33 of the 78 patients who underwent above or below knee ampu-
tations after failed revascularization were surveyed. The attitudes of the
patients who were lost to follow-up or who did not survive are crucial to
the validity of the authors’ conclusion and limit the general applicability
of this study.
Characterization of the Inflammatory Cells in Ascending Thoracic
Aortic Aneurysms and in Patients with Marfan Syndrome, Familial
Thoracic Aortic Aneurysms, and Sporadic Aneurysms
He R, Guo D-C, SunW, et al. J Thoracic Cardiovasc Surg 2008;136:922-9.
Conclusion: Inflammatory cell infiltrates contribute to the pathogen-
esis of thoracic aortic aneurysm (TAA). Stimulation of T lymphocytes may
contribute to the initial immune response leading to this inflammatory
infiltrate.
Summary: The etiologies of abdominal aortic aneurysms (AAAs) and
TAAs are likely not the same. Although some TAAs are degenerative, as are
AAAs, significant numbers of TAAs affect a younger population in which the
primary pathology is a genetically influenced degeneration of the medial
layer of the arterial wall. Histologically, this is represented by loss of smooth
muscle cells, increased accumulation of proteoglycans, and diminished num-
bers of and fragmentation of elastic fibers. Such patients are known to have
an inflammatory infiltrate in the aortic wall. In this study the authors sought
to characterize this inflammatory infiltrate.
Full aortic segments in patients undergoing elective repair with Marfan
syndrome (n  5), familial thoracic aortic aneurysms (n  6), and thoracic
aortic aneurysms (n  9) were collected at the time of operative repair. The
study also used five control aortas that were obtained from patients who died
of a process unrelated to aortic dissection and who had no evidence of sepsis
at the time of death. The aortic samples were subjected to immunohisto-
chemistry staining using antibodies against markers of macrophages and
lymphocytes. Polymerase chain reaction analysis was used to quantify the
expression level of T-cell receptor -chain variable region gene. Mutations
in this gene lead to varied phenotypes associated with TAAs and thoracic
dissections.
Immunohistochemistry analysis demonstrated the adventitia and me-
dia from the aortas of patients with Marfan syndrome, familial TAA, as well
as sporadic cases of TAAs had increased numbers of T lymphocytes and
macrophages compared with the control aortas. There was an inverse
correlation with age with the number of T cells and macrophages in the
aortic media. Profiling of the T-cell receptors suggested a similar clonal
nature of T cells in the aortic wall, regardless of whether the patient had
sporadic aortic disease, Marfan syndrome, or familial TAA. More inflamma-
tory cells were present in the aortas of patients with genetic defects than in
patients with sporadic aneurysms.
Comment: The number of macrophages and inflammatory T lympho-
cytes in the aortic media of the samples used in this study negatively
correlated with the patient’s age. This raises the possibility that inflammatory
cells may contribute to disease progression and aortic expansion in patients
with TAAs. An alternative explanation is that the inflammatory infiltrate
correlate with aortic dilatation and parallel the dilatation and corresponding
pathologic changes but in themselves do not contribute to disease progres-
sion. However, no correlation existed between aortic diameter and the
number of inflammatory cells, implying that the inflammatory infiltrate is
not simply a result of the aortic dilatation and irritation of the tissues from
enlargement of the aorta. Clearly, the biologic activity of the macrophages
and T cells present in the aortic media of patients with TAAs needs to be
further characterized. The authors also point out that an immune-mediated
